# Jonathan Spicer

Source: https://onco.cc/people/jonathan-spicer/  
OnCo record `jonathan-spicer` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The surgeon on CheckMate 816 who showed neoadjuvant immunotherapy does not make lung cancer operations harder.

## Summary

Jonathan Spicer led the surgical analyses of CheckMate 816, demonstrating that neoadjuvant nivolumab plus chemotherapy did not delay or complicate surgery and increased the rate of complete resection, which removed a key objection to neoadjuvant immunotherapy. He co-authored the five-year update and leads perioperative surgical research at McGill.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lung; surgery; neoadjuvant
- Role: Thoracic Surgeon and Associate Professor of Surgery, McGill University Health Centre
- Specialisms: Thoracic surgery; Neoadjuvant immunotherapy; Surgical outcomes in trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Spicer%20JD%5BAuthor%5D%20neoadjuvant%20lung%20surgery

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [Rosalind and Morris Goodman Cancer Institute, McGill University](https://onco.cc/institutions/mcgill-goodman/)
- trials: [CheckMate 816](https://onco.cc/trials/checkmate-816/)
- key papers: [CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery](https://onco.cc/key-papers/paper-checkmate-816-nejm-2022/)

---
JSON: https://onco.cc/api/v1/entities/jonathan-spicer.json